Ernexa Therapeutics Appoints Director Robert J. Spiegel

What Happened
Ernexa Therapeutics Inc. announced on September 14, 2026 that, upon recommendation of its Nominating and Corporate Governance Committee, it appointed Robert J. Spiegel, M.D. to serve as a member of the Board of Directors effective immediately. Dr. Spiegel will serve until his successor is elected and qualified or until earlier death, resignation, or removal. His compensation will follow the Company’s Board of Directors Compensation Plan adopted effective August 15, 2026 (described in Ernexa’s Form 10-Q for the quarter ended June 30, 2026 filed August 6, 2026).

Key Details

• Appointment date: September 14, 2026; effective immediately.
• Compensation: Governed by the Board of Directors Compensation Plan (adopted Aug. 15, 2026) as previously disclosed in the 10-Q filed Aug. 6, 2026.
• No related-party arrangements: The company reported no arrangements or understandings with others regarding the appointment, no family relationship with other directors or officers, and no reportable transactions under Item 404(a) of Regulation S-K.

Why It Matters
This 8-K reports a change to Ernexa’s board composition—useful for investors tracking corporate governance and oversight. The filing indicates the appointment follows the company’s established compensation plan (so no new special compensation was disclosed) and that there are no apparent related-party conflicts tied to this appointment.